These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 6209513)

  • 1. High-dose intravenous gammaglobulin for Kawasaki disease.
    Furusho K; Kamiya T; Nakano H; Kiyosawa N; Shinomiya K; Hayashidera T; Tamura T; Hirose O; Manabe Y; Yokoyama T
    Lancet; 1984 Nov; 2(8411):1055-8. PubMed ID: 6209513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose gammaglobulin therapy for Kawasaki disease.
    Nagashima M; Matsushima M; Matsuoka H; Ogawa A; Okumura N
    J Pediatr; 1987 May; 110(5):710-2. PubMed ID: 2437278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on coronary artery lesions in patients with Kawasaki disease: recent 9 years' experience].
    Wu JR; Hwang KP; Tu JG; Dai ZK; Huang TY
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1993 Jan; 9(1):27-38. PubMed ID: 7682261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N; Sugimura T; Akagi T; Yamakawa R; Hashino K; Eto G; Iemura M; Ishii M; Kato H
    Pediatr Int; 1999 Feb; 41(1):1-7. PubMed ID: 10200128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of pharmacological treatment of Kawasaki disease.
    Onouchi Z; Kawasaki T
    Drugs; 1999 Nov; 58(5):813-22. PubMed ID: 10595862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of Kawasaki syndrome with intravenous gamma globulin.
    Newburger JW; Takahashi M; Burns JC; Beiser AS; Chung KJ; Duffy CE; Glode MP; Mason WH; Reddy V; Sanders SP
    N Engl J Med; 1986 Aug; 315(6):341-7. PubMed ID: 2426590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin.
    Leung DY; Burns JC; Newburger JW; Geha RS
    J Clin Invest; 1987 Feb; 79(2):468-72. PubMed ID: 2433307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
    Terai M; Shulman ST
    J Pediatr; 1997 Dec; 131(6):888-93. PubMed ID: 9427895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Kawasaki disease in the British Isles.
    Dhillon R; Newton L; Rudd PT; Hall SM
    Arch Dis Child; 1993 Dec; 69(6):631-6; discussion 637-8. PubMed ID: 8285773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.
    Hsu CH; Chen MR; Hwang FY; Kao HA; Hung HY; Hsu CH
    Pediatr Infect Dis J; 1993 Jun; 12(6):509-12. PubMed ID: 8345983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
    Miura M; Ohki H; Tsuchihashi T; Yamagishi H; Katada Y; Yamada K; Yamashita Y; Sugaya A; Komiyama O; Shiro H
    Arch Dis Child; 2004 Aug; 89(8):776-80. PubMed ID: 15269082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of peripheral blood macrophages/monocytes in Kawasaki disease by intravenous gammaglobulin.
    Furukawa S; Matsubara T; Jujoh K; Sasai K; Nakachi S; Sugawara T; Yabuta K; Kato H
    Eur J Pediatr; 1990 Nov; 150(1):43-7. PubMed ID: 1706665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous gamma-globulin for Kawasaki disease.
    Furusho K; Kamiya T; Nakano H; Kiyosawa N; Shinomiya K; Hayashidera T; Tamura T; Hirose O; Manabe Y; Yokoyama T
    Acta Paediatr Jpn; 1991 Dec; 33(6):799-804. PubMed ID: 1801560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical manifestations and effects of IVGG in patients with Kawasaki disease].
    Hwang KP; Wu JR; Huang LY; Liou CC; Huang TY
    Kaohsiung J Med Sci; 1996 Mar; 12(3):159-66. PubMed ID: 8709183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki Disease.
    Nishihara S; Ishibashi K; Iribe K; Matsuda I
    Lancet; 1988 Oct; 2(8617):973. PubMed ID: 2459575
    [No Abstract]   [Full Text] [Related]  

  • 17. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
    Furukawa S; Matsubara T; Umezawa Y; Motohashi T; Ino T; Yabuta K
    Eur J Pediatr; 1994 Sep; 153(9):663-7. PubMed ID: 7957426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kawasaki syndrome in 18 children in the west of Scotland.
    Odaibo FS; Goel KM
    Scott Med J; 1991 Aug; 36(4):107-9. PubMed ID: 1720900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New hope for children with Kawasaki disease.
    Lux KM
    J Pediatr Nurs; 1991 Jun; 6(3):159-65. PubMed ID: 1710660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic and coronary angiographic assessment of effectiveness of aspirin or aspirin-and-gammaglobulin in Kawasaki disease.
    Haneda N; Mori C
    Acta Paediatr Jpn; 1993 Aug; 35(4):294-7. PubMed ID: 7691025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.